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Abstract 28 
Background: Act d 12 (11S globulin) and Act d 13 (2S albumin) are two relevant allergens 29 
from kiwi seeds recently discovered. Their inclusion in component-resolved diagnosis of 30 
kiwifruit allergy could improve the diagnostic sensitivity and the management of kiwifruit 31 
allergic patients.  32 
Objective: To perform a comprehensive structural and immunological characterization of 33 
purified Act d 12 and Act d 13 from kiwi seeds. 34 
Methods: Sera from 55 well-defined kiwifruit allergic patients were used. Act d 12 and Act 35 
d 13 were purified by conventional chromatographic procedures. Circular dichroism, mass 36 
spectrometry, concanavalin A detection, immunoblotting, enzyme-linked immunosorbent 37 
assays, basophil activation tests and IgE-inhibition experiments were used for structural 38 
and immunological characterization and IgE cross-reactivity studies.  39 
Results: Act d 12 and Act d 13 were purified from kiwi seeds to homogeneity by 40 
combining size-exclusion, ion-exchange and RP-HPLC chromatographies. Purified Act d 41 
12 and Act d 13 preserve the structural integrity and display typical features of their 42 
homologous counterparts from the 11S globulin and 2S albumin protein families, 43 
respectively. Both purified allergens retain the capacity to bind serum IgE from kiwifruit 44 
allergic patients, induce IgE cross-linking in effector circulating basophils and display in 45 
vitro IgE cross- reactivity with homologous counterparts from peanut and tree nuts.  46 
Conclusion: Purified Act d 12 and Act d 13 from kiwi seeds are well-defined molecules 47 
involved in in vitro IgE cross-reactivity with peanut and tree nuts. Their inclusion in 48 
component-resolved diagnosis of kiwifruit allergy might well contribute to improve the 49 
diagnostic sensitivity and the management of kiwifruit allergic patients.  50 
Sirvent et al. 
 
3 
 
Key words: kiwifruit allergy, 11S globulin Act d 12, 2S albumin Act d 13, component-51 
resolved diagnosis, peanut and tree nuts cross-reactivity.  52 
 53 
Abbreviations 54 
CBS: Coomassie blue staining 55 
CD: Circular dichroism 56 
CRD: Component-resolved diagnosis 57 
DBPCFC: double-blind placebo-controlled food challenges  58 
ELISA: Enzyme-linked immunosorbent assay 59 
MS: Mass spectrometry  60 
OAS: Oral allergy syndrome 61 
OD: Optical density 62 
SPT: Skin prick test  63 
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Introduction 64 
IgE-mediated food allergy is a common health problem affecting around 5% of adults and 65 
8% of children in industrialized countries (1). The consumption of kiwifruit (Actinidia 66 
deliciosa) has significantly risen over the last decades in western countries (2), likely due 67 
to the reported beneficial effects associated to the inclusion of this fruit into the diet (3). 68 
Since the first case of kiwifruit allergy was reported in 1981 (4), the prevalence has 69 
enormously increased, being currently considered among the top 10 food allergies (2, 5, 70 
6).  71 
The gold standard approach to accurately diagnose kiwifruit allergy remains 72 
double-blind placebo-controlled food challenges (DBPCFC), but the main inconveniences 73 
include the difficulty to mask kiwifruit and the risk of anaphylactic reactions (7). Different 74 
attempts at improving the diagnosis of kiwifruit allergy have been performed (2, 5, 6). Prick 75 
to prick test with fresh kiwifruit is a highly sensitive method for diagnosis (83-100%) with 76 
low specificity (around 31%). In contrast, skin prick test (SPT) and in vitro serum specific-77 
IgE determinations with commercially available kiwifruit extracts improved specificity (40-78 
45%) but showed low sensitivity (17-60%). Recent studies showed component-resolved 79 
diagnosis (CRD) with purified kiwifruit allergens as an alternative not only to increase the 80 
diagnostic sensitivity (up to 65%) but also to link specific IgE-sensitization patterns with 81 
clinical features (2, 5, 8).   82 
Up to date, 13 kiwifruit allergens have been described according to the 83 
International Union of Immunological Societies (IUIS) allergen nomenclature subcommittee 84 
(www.allergen.org) (6, 9, 10). Almost all the kiwifruit allergens were initially described in 85 
the kiwi pulp (Act d 1 to Act d 11) with the exception of Act d 10 (LTP) that was also 86 
reported in kiwi seeds (11). We have recently demonstrated that kiwi seeds, which are 87 
usually ingested together with the kiwi pulp, constitute a source of additional potent 88 
allergens such as the 11S globulin Act d 12 and the 2S albumin Act d 13(10). Around 85% 89 
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of the kiwifruit allergic patients were sensitized to at least one of these allergens from kiwi 90 
seeds, suggesting that their inclusion in CRD of kiwifruit allergy might well contribute to 91 
improve the diagnostic sensitivity. Prior to the inclusion of these molecules in CRD 92 
approaches, a comprehensive characterization of both purified allergens is mandatory. 93 
The aim of this study was to characterize from structural and immunological point 94 
of view the purified Act d 12 and Act d 13 from kiwi seeds and to investigate the potential 95 
implication of these allergens in IgE cross-reactivity involving kiwi, peanut and tree nuts.  96 
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Material and methods 97 
Patients’ sera 98 
Serum samples were obtained from a well-defined cohort of 55 Kiwifruit allergic patients, 99 
controls from pollen-allergic patients and non-atopic donors from the Allergy Service of 100 
Hospital Carlos Haya, Málaga, Spain, and Hospitals Fundación Jiménez Díaz and Infanta 101 
Leonor, Madrid, Spain (10). The study was approved by the Ethic Committee of the 3 102 
Hospitals, and written informed consent was obtained from all subjects. 103 
 104 
Detailed protocols for the purification of Act d 12 and Act d 13, protein extracts, analytical 105 
procedures, immunoblotting, ELISA, basophil activation test, carbohydrate detection, 106 
circular dichroism (CD), preparation of phospholipid vesicles, isolation of lipids from kiwi 107 
seeds, simulated gastric and intestinal digestion methods are fully described in the online 108 
repository material of this article.  109 
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Results  110 
Act d 12 and Act d 13 display common structural features to their homologous 111 
counterparts from the 11S globulin and 2S albumin protein families 112 
Act d 12 (11S globulin) and Act d 13 (2S albumin) of around 51 and 12 kDa, respectively, 113 
are two novel allergens contained kiwi seeds extract that display IgE-reactivity in 114 
immunoblotting with a pool of sera from kiwifruit allergic patients (Fig. 1A). We purified 115 
both allergens to homogeneity following the sequential chromatographic steps described in 116 
the online repository (Supplementary Fig. 1). The purity and structural integrity of the 117 
purified Act d 12 and Act d 13 was assayed by CBS and IgE-binding analysis after SDS-118 
PAGE (Supplementary Fig. 1B,C), Edman degradation and MS-fingerprint analysis (data 119 
not shown). Both purified allergens consisted of two polypeptide subunits of around 32 and 120 
20 kDa (Act d 12) and of around 8 and 4 kDa (Act d 13) that can be separated under 121 
reducing conditions (Fig. 1B). MS of purified Act d 12 yielded a heterogeneous profile with 122 
two main peaks at 50207.3 and 52280.5 Da (Fig. 1C). For Act d 13, a single peak at 123 
11359.0 Da was obtained (Fig. 1C).  None of the purified allergens carried glycan moieties 124 
as demonstrated by negative staining with the lectin Concanavalin A (Fig. 1D). The CD 125 
spectra in the far-UV of purified Act d 12 and Act d 13 showed that both allergens display a 126 
structured folding (Fig. 1E). Temperature-dependent unfolding experiments (from 20 ºC to 127 
80 ºC) of Act d 12 and Act d 13 revealed slight and reversible changes of secondary 128 
structure, indicating that both allergens are highly stable to thermal denaturation (Figure 129 
1E). 130 
 131 
Act d 12 and Act d 13 show different resistance to gastric and intestinal digestion  132 
Purified Act d 12 and Act d 13 were subjected to in vitro simulated gastric and intestinal 133 
digestions alone or in the presence of lipids from kiwi seeds, PC or PG vesicles. Gastric 134 
digestion of Act d 12 rendered fragments of around 17, 13 and 10 kDa within the first 135 
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seconds that were completely digested after 2 h of treatment (Fig. 2A). No differences 136 
were observed in the presence of kiwi lipids or PC vesicles. In contrast, the addition of PG 137 
vesicles significantly increased the resistance of Act d 12 to gastric digestion remaining the 138 
allergen intact even after 2 h of treatment (Fig. 2A). Act d 13 was very resistant to gastric 139 
treatment as it was only digested after 16 h without significant differences in the presence 140 
of kiwi lipids, PC or PG vesicles (Fig 2A). Intestinal digestion of Act d 12 resulted in the 141 
rapid appearance of proteolytic fragments of around 40, 34 and 16 kDa that were 142 
detectable even after 16 h of treatment. The presence of kiwi lipids, PC or PG vesicles did 143 
not significantly modify the resistance of Act d 12 to intestinal digestion (Fig. 2B). Act d 13 144 
was very resistance also to intestinal degradation and after 16 h of treatment 53%, 54%, 145 
42% and 51% of Act d 13 remained undigested when assayed alone, in the presence of 146 
kiwi lipids, PC or PG vesicles, respectively, as determined by scanning densitometry (Fig. 147 
2B). 148 
 149 
Act d 12 and Act d 13 retain IgE-binding capacity and allergenicity 150 
The IgE-binding capacity of purified Act d 12 and Act d 13 from kiwi seeds was 151 
demonstrated by ELISA and immunoblotting with the cohort of 55 kiwifruit allergic patients 152 
(10). When we plotted the obtained ELISA values for Act d 12 and Act d 13 versus the 153 
corresponding immunoblotting data (arbitrary units determined by scanning densitometry 154 
and relative to patient 1 for Act d 12 and to patient 43 for Act d 13, respectively), we found 155 
significant correlations in both cases (Fig. 3A). Purified Act d 12 and Act d 13 were 156 
recognized by 70.9% and 18.2% of the tested patients, respectively, in immunoblotting 157 
(Fig. 3B).  158 
To quantify the contribution of Act d 12 and Act d 13 to the total allergenicity of the 159 
kiwi seed extract, we performed ELISA inhibition experiments. The IgE binding to kiwi 160 
seeds extract was notably abolished after pre-incubation of the pool of sera with purified 161 
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Act d 12 (53%) (Fig. 3C). When Act d 13 was used as inhibitor, a 34% of inhibition was 162 
reached, and when the pool of sera was pre-incubated with the mixture of both allergens, 163 
the inhibition was around 80% (Fig. 3C).   164 
The allergenic capacity of Act d 12 and Act d 13 was assessed by in vitro BAT. 165 
Both purified allergens demonstrated capacity to induce IgE cross-linking in effector 166 
circulating basophils (Fig. 3D). Kiwifruit allergic patients with specific IgE to kiwi seeds 167 
extract and to Act d 12 or Act d 13 showed positive BAT with kiwi seeds extract, purified 168 
Act d 12 or Act d 13 with median SI values of x± y, z ± w and m ± n, respectively (Fig 3D). 169 
 170 
Act d 12 and Act d 13 from kiwi seeds show in vitro IgE cross-reactivity with homologous 171 
counterparts from peanut and tree nuts 172 
We performed in vitro IgE-inhibition experiments in immunoblotting. We pooled the sera 173 
from kiwifruit allergic patients sensitized to peanut and tree nuts into two groups (Table I): 174 
i) patients with specific IgE to Act d 12, and ii) patients with specific IgE to Act d 13. The 175 
IgE reactivity to the protein of 51 kDa in kiwi seeds extract was totally abolished when the 176 
pool of sera from patients sensitized to Act d 12 was preadsorbed to kiwi seeds extract or 177 
to the purified Act d 12 (Fig. 4A). The IgE-binding to purified Act d 12 was significantly 178 
inhibited by peanut, almond, hazelnut and walnut (86%, 67%, 66% and 65%, respectively) 179 
and completely inhibited by kiwi seeds extract or purified Act d 12 (Fig. 4B). The IgE-180 
reactivity to the protein of 12 kDa in kiwi seeds extract was also completely inhibited when 181 
the pool of sera from patients sensitized to Act d 13 was preadsorbed to kiwi seeds extract 182 
or to the purified Act d 13 (Fig. 4C). Inhibition of the IgE-binding to the purified Act d 13 183 
was observed with walnut (85%), peanut (70%) and almond (49%) but not with hazelnut 184 
(10%) (Fig. 4D). Complete inhibition was obtained with kiwi seeds or the purified Act d 13.  185 
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Discussion  186 
In this study, we performed a comprehensive structural and immunological 187 
characterization of purified Act d 12 and Act d 13 from kiwi seeds. Our results 188 
demonstrated that purified Act d 12 and Act d 13 preserve the structural integrity and 189 
display typical features of their homologous counterparts from the 11S globulin and 2S 190 
albumin protein families, respectively. Both purified allergens retained the capacity to bind 191 
serum IgE from kiwifruit allergic patients in ELISA and immunoblotting, induced IgE cross-192 
linking in effector circulating basophils and displayed in vitro IgE-cross reactivity with 193 
homologous counterparts from peanut and tree nuts. The availability of purified Act d 12 194 
and Act d 13 from kiwi seeds as well-defined molecules and their inclusion in CRD 195 
approaches might well contribute to improve the diagnostic sensitivity of kiwifruit allergy. 196 
Further detailed studies are required to confirm the clinical relevance of the in vitro IgE 197 
cross-reactivity among kiwi, peanut and tree nuts involving Act d 12 and Act d 13, which 198 
might also have essential implications in the management of kiwifruit allergic patients.  199 
The prevalence of kiwifruit allergy has significantly increased over the last decades 200 
in western countries (2, 5). Kiwifruit allergy is frequently associated to pollen or latex 201 
allergy and clinical symptoms vary from mild local oral allergy syndrome (OAS) (12) to 202 
severe systemic reactions including anaphylaxis (13, 14), which compounds accurate 203 
diagnosis. Diagnosis of kiwifruit allergy has significantly improved during the last years (2, 204 
5, 6, 8). However, the main drawbacks are still the classical difficulties associated to 205 
DBPCFC, the low specificity for prick to prick tests and the low sensitivity for in vivo SPT 206 
and in vitro serum specific-IgE determinations. Low sensitivity of diagnostic tests has been 207 
attributed to the different allergenic protein content of the kiwi varieties (15) and to the lack 208 
of relevant allergens in the used commercial kiwifruit extracts (6). At this regard, we 209 
recently showed that kiwi seeds represent an important allergenic source to be considered 210 
in the context of kiwifruit allergy as they contain relevant allergens such as Act d 12 or Act 211 
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d 13 (10). Seeds from other species are also well-recognized potent inducers of food 212 
allergy due to their high content of very stable seed-specific storage proteins (16-18).  213 
The use of well-defined purified allergens is very useful to improve diagnosis, 214 
management and treatment of allergic patients (19, 20). We purified and deeply 215 
characterized Act d 12 and Act d 13 from kiwi seeds. 11S globulins and 2S albumins are 216 
non-glycosylated and very stable seed-specific storage proteins composed of two 217 
polypeptide chains linked by disulphide bridges, structural features that were retained in 218 
purified Act d 12 and Act d 13. Other members from these protein families have been 219 
previously described as potent food allergens able to induce primary sensitization at the 220 
gastrointestinal level (21-27). To assess the capacity of Act d 12 an Act d 13 to reach the 221 
intestinal gut as intact molecules able to interact with immune system cells, we subjected 222 
purified Act d 12 and Act d 13 to different protease treatments. Act d 13, as other 2S 223 
albumins such as Sin a 1 (28) BnIb (29), or Ber e 1 (30), was very resistance to simulated 224 
gastric and intestinal digestions in all the assayed conditions. In contrast, Act d 12 was 225 
rapidly digested by simulated gastric fluid showing higher resistance to intestinal 226 
degradation as previously shown for homologous counterparts (31). Interestingly, the 227 
presence of PG vesicles significantly increased the resistance of Act d 12 to gastric 228 
digestion without affecting intestinal treatments, suggesting that acidic phospholipids could 229 
specifically hide the pepsine-sensitive proteolytic sites of Act d 12 and increase its 230 
resistance to gastric digestions.  231 
Act d 12 represents a major allergen recognized by more than 50% of the 55 232 
kiwifruit allergic patients included in this study, whereas Act d 13 is a minor allergen. There 233 
was a significant correlation between the reactivity observed in ELISA and immunoblotting 234 
for both allergens. A mixture of Act d 12 and Act d 13 inhibited around 80% of the IgE-235 
reactivity to kiwi seeds extract, indicating that most of the IgE epitopes of kiwi seeds are 236 
represented within these two allergens in the tested populations. Importantly, we also 237 
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demonstrated that Act d 12 and Act d 13 were able to induce in vitro IgE cross-linking in 238 
circulating basophils from kiwifruit allergic patients, thus demonstrating that both purified 239 
allergens retain allergenic capacity. 240 
Around 44 % of the patients included in this study were also allergic to tree nuts or 241 
peanut. Among these patients, 91.6 % (22/24) were sensitized to Act d 12 or Act d 13, 242 
suggesting a potential implication of these allergens in cross-reactivity with peanut and 243 
tree nuts. In vitro IgE-inhibition experiments demonstrated that purified Act d 12 and Act d 244 
13 conserved common epitopes of homologous counterparts from peanut, almond, 245 
hazelnut or walnut, suggesting that Act d 12 and Act d 13 might be involved in cross-246 
reactivity with these allergenic sources. Further detailed studies are required to elucidate 247 
the potential clinical relevance of the observed in vitro IgE-cross reactivity. Different 248 
studies have previously shown that 11S globulins and 2S albumins constitute two families 249 
of allergenic proteins that might be involved in IgE cross-reactivity among mustard, peanut 250 
and tree nuts (32-35).  251 
Collectively, our data indicated that Act d 12 and Act d 13 purified from kiwi seeds 252 
constitute well-defined molecules that might be included in future CRD of kiwifruit allergy, 253 
which could contribute to improve the diagnostic sensitivity. Purified Act d 12 and Act d 13 254 
showed in vitro IgE cross-reactivity with homologous counterparts from tree nuts and 255 
peanut. Further studies are required to confirm the clinical impact of this fact, which might 256 
be also relevant for the management of kiwifruit allergic patients. 257 
258 
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Sera Patient Sex/Age Kiwifruit Other food Pollen Tree nuts and 
pool number (y) Symptoms Kiwi Act d 12 Act d 13 allergies allergy peanut symptoms Peanut Almond Hazelnut Walnut
1 F/26 OAS 0.068 0.212 0.029 r,n,t,p Yes OAS 12 12 12 Neg
2 M/39 U 0.069 0.692 0.073 r,n,p Yes A, AN 12 Neg 48 Neg
3 F/19 OAS 0.066 0.52 0.051 r,n,p Yes OAS 9 20 12 9
4 F/21 OAS 0.02 0.205 0.054 r,n,p,b,t,pn,gr Yes OAS 18 35 15 42
5 F/39 OAS 0.142 0.133 0.028 n,p Yes OAS ND ND ND ND
6 M/27 U 0.146 0 0.185 r,n,p Yes OAS Neg Neg 22 Neg
7 F/20 OAS 0.063 0.069 0.342 r,n,p Yes OAS 12 Neg 10 12
8 F/17 OAS 0.212 0.053 0.264 r,n Yes OAS ND ND ND ND
9 F/36 OAS 0.112 0.068 0.181 r,n,p,tr No OAS 12 Neg 22 22
10 M/37 OAS 0.235 0.439 0.223 r,n,p,m,f Yes AN, OAS 22 22 22 Neg 
y: year; M/F: male/female;  Neg: negative; AN: anaphylaxia;  OAS: oral allergy syndrome; U: urticaria; av: avocado; b: banana; f: fig; gr: grape; n: tree nuts including almond;  p: peanut; pn: 
pineapple; r: rosaceae excluding almond; t: tomato; tr: tropical; ND: not done
* Skin prick test wheal area in mm2
†Specific IgE determined in ELISA as OD at 492 nm
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Table I. Clinical features of the patients selected for in vitro IgE inhibition experiments 
SPT*
ELISA†
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Figure legends 384 
 385 
Figure 1. Structural characterization of purified Act d 12 and Act d 13. (A) CBS and IgE 386 
immunoblotting with a pool of sera from kiwifruit allergic patients after SDS-PAGE of kiwi 387 
seeds extract. (B) CBS and IgE immunoblotting after SDS-PAGE of purified Act d 12 or 388 
purified Act d 13 in the absence or presence of β-mercaptoethanol (me). (C) Molecular 389 
mass determination of the purified Act d 12 and Act d 13 by MS. (D) Sugar staining with 390 
biotinylated ConA after SDS-PAGE of kiwi seeds extract, purified Act d 12, Act d 13, Ole e 391 
1 (positive control) and Sin a 1 (negative control). (E) CD spectra of purified Act d 12 and 392 
Act d 13 in the far-UV at 20 ºC, at 85 ºC and cooling down again at 20 °C. Secondary 393 
structure contributions (α H, α-helix; β S, β-sheet; β T, β-turn; RC, random coil) are shown. 394 
 395 
Figure 2. Simulated gastric and intestinal digestion of purified Act d 12 and Act d 13. 396 
Coomassie blue staining of the gastric digestion (A) or intestinal digestion (B) products of 397 
purified Act d 12 or Act d 13 alone or in the presence of kiwi lipids (+KL), PC (+PC) or PG 398 
(+PG) vesicles. Molecular markers are indicated in kDa in the left side. 399 
 400 
Figure 3. Allergenic characterization of purified Act d 12 and Act d 13. (A) Correlation 401 
between ELISA and immunoblotting reactivity for the purified allergens for the 55 sera from 402 
patients allergic to kiwifruit. OD, optical density at 492 nm. AU, arbitrary units showing the 403 
relative intensity for each serum after normalization of the values determined by scanning 404 
densitometry with those obtained for serum 1 (Act d 12) and 43 (Act d 13). (B) 405 
Immublotting for purified Act d 12 and Act d 13 with the individual sera. C, serum from a 406 
non-atopic subject. (C) Inhibition of the IgE-binding of a pool of sera from kiwifruit allergic 407 
patients to kiwi seeds extracts with (1 mg/mL) kiwi seeds extract, (20 micrograms/mL) of 408 
purified Act d 12, Act d 13 or an equal mixture of both purified allergens. (D) Basophils 409 
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activation test using kiwi seeds extract and purified Act d 12 and Act d 13; C+, positive 410 
control with histamine; horizontal dashed line represent the obtained values for the 411 
negative control with PBS. 412 
 413 
Figure 4. Immunoblotting inhibition experiments. Inhibition of the IgE-binding to Act d 12 414 
contained in kiwi seeds extract (A) or to purified Act d 12 (B) by the indicated inhibitors 415 
when using a pool of sera from kiwifruit allergic patients sensitized to Act d 12. Inhibition of 416 
the IgE-binding to Act d 13 contained in kiwi seeds extract (C) or to purified Act d 13 (D) by 417 
the indicated inhibitors when using a pool of sera from kiwifruit allergic patients sensitized 418 
to Act d 13. BSA was used as negative control of inhibition. Percentages of inhibition are 419 
shown at the bottom of the figures (B) and (D). 420 


Fig 3D. Faltaría 
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Methods 27 
Purification of 11S globulin Act d 12 and 2S albumin Act d 13 and protein extracts  28 
Kiwi seed extract was applied onto a Sephadex G-50 column equilibrated in 0.15 M 29 
ammonium bicarbonate, pH 8.0. Fractions containing protein bands of around 51 and 30 
12 kDa were visualized by Coomassie blue staining (CBS) after SDS-PAGE and 31 
pooled in two independent batches, respectively (Supplementary Figure 1). The batch 32 
1 containing the 11S globulin Act d 12 was further subjected to ion-exchange 33 
chromatography on a DEAE-Cellulose column equilibrated in 20 mM ammonium 34 
bicarbonate buffer, pH 8.0. Proteins were eluted with a gradient from 20 to 500 mM 35 
ammonium bicarbonate buffer, pH 8.0. The fractions containing the 11S globulin Act d 36 
12 were pooled together. The batch 2 containing the 2S albumin Act d 13 was resolved 37 
on a reverse-phase high-performance liquid chromatography (RP-HPLC) nucleosil C-38 
18 column with a gradient (25-45 %) of acetonitrile in 0.1% trifluoracetic acid. SDS-39 
PAGE and CBS were carried out for all purification steps. The IgE reactivity of Act d 12 40 
and Act d 13 was analyzed for each purification step by using a pool of sera from 41 
kiwifruit allergic patients diluted 1/3. Protein extracts for kiwi seeds, almond, hazelnut, 42 
peanut and walnut were obtained as previously described (1-3) 43 
 44 
Analytical procedures  45 
SDS-PAGE was performed in 17 % polyacrylamide gels. Proteins were visualized by 46 
Coomassie blue staining (CBS) or alternatively transferred to nitrocellulose membranes 47 
(Amersham). The protein concentration was determined using the method of 48 
bicinchoninic acid (Pierce Chemical Co) or by Lowry method. Molecular mass 49 
determinations were performed by mass spectrometry (MS) using a Bruker Reflex IV 50 
matrix-assisted laser-desorption ionization time-of-flight mass spectrometer (Bruker- 51 
Franzen Analytik), as described (4).  52 
 53 
 54 
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Immunoblotting 55 
Immunodetection of purified Act d 12 and Act d 13 after SDS-PAGE was performed 56 
with serum from patients allergic to kiwifruit (1/3 diluted) as described (5). The binding 57 
of human IgE was detected by mouse anti-human IgE antibodies (diluted 1:5000; ALK-58 
Abelló), followed by horseradish peroxidase-labelled goat anti-mouse IgG (diluted 59 
1:5000; Pierce). The signal was developed with the ECL-Western blotting reagent 60 
(Amersham). For IgE-inhibition experiments the pool of sera (1/3 diluted) was 61 
preadsorbed with 1 mg/mL of whole extracts or 20 µg/mL of purified allergens, 62 
overnight at 4ºC. BSA was used as negative control of inhibition. Volummograms of the 63 
reactive bands were analyzed by scanning densitometry using Multigauge software 64 
(Fujifilm) and the obtained values were normalized to patient 1 (Act d 12) or to patient 65 
43 (Act d 13). 66 
 67 
ELISA 68 
IgE quantitation was performed by ELISA in microtiter plates (Costar) coated with 100 69 
µl/well of purified Act d 12 or Act d 13 (2 µg/mL) or kiwi seeds extract (20 µg/mL) (5). 70 
Plates were incubated with serum from kiwifruit allergic patients (1/3 diluted) and 71 
binding of IgE was detected as described above. Peroxidase reaction was developed 72 
using fresh enzyme substrate and measuring optical density (OD) at 492 nm. Each 73 
value was calculated as the mean of 2 determinations after blank subtraction. OD 74 
values <0.1 were considered negative responses. For IgE-inhibition experiments, the 75 
corresponding pool of sera (1/3 diluted) was preadsorbed to 20 µg/mL of purified Act d 76 
12 or Act d 13, or a mixture of both or to 1mg/ml of kiwi seeds extract prior to 77 
incubation with plates coated with kiwi seeds extract.  78 
 79 
Basophil activation test 80 
Basophil activation tests (BAT) were performed with kiwi seeds extract (x mg/mL), 81 
purified Act d 12 (y mg/ml) and Act d 13 (z mg/ml) using heparinized whole blood from 82 
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kiwifruit allergic patients and healthy controls as described.(6) Anti-human IgE 83 
antibodies (BD PharMingen) and physiologic saline solutions were used as positive 84 
and negative controls, respectively. Stimulation indexes (SI) were calculated as the 85 
ratio between the percentage of degranulated basophils with the stimulus and the 86 
negative control. SI values higher than 2 were considered positive according to 87 
previously established receiver operating characteristic curves comparing BAT results 88 
between patients and control subjects (6). 89 
 90 
Carbohydrate detection and circular dichroism 91 
Carbohydrate detection of protein transferred to nitrocellulose membranes was 92 
performed by using a biotinylated concanavalin A solution. The staining was developed 93 
by horseradish peroxidase reaction with 0.05% diaminobenzidine/0.03% of 30% H2O2 94 
in Tris/NaCl reaction buffer. The circular dichroism (CD) spectra were obtained using a 95 
JASCO J-715 spectropolarimeter  (Japan Spectroscopic Co.) fitted with a 150 W xenon 96 
lamp and connected to a Nestlab RTE-111 thermostabilizer bath, at 20 °C and 85 ºC, 97 
as described (7). Far-UV spectra (190−250 nm) were registered using optical-path cell 98 
of 0.1 cm. The protein concentration was 0.2 mg/mL in 20 mM ammonium bicarbonate, 99 
pH 8. Mean residue mass ellipticities were calculated based on 110 as the average 100 
molecular mass/residue and expressed in terms of θ (degree × cm2 × dmol−1). Final 101 
spectra were corrected by subtracting the corresponding baseline spectrum obtained 102 
for the buffer alone under identical conditions. 103 
 104 
Preparation of phospholipid vesicles and isolation of lipids from kiwi seeds  105 
Ten milligrams of dried phosphatidylcholine (PC), phosphatidylglycerol (PG) (Avanti 106 
Polar Lipids) or kiwi lipids were rehydrated with 1 mL of simulated gastric fluid (SGF), 107 
(30 mM NaCl, 48 mM HCl, pH 1.2), or simulated intestinal fluid (SIF), (4 mM sodium 108 
taurocholate, 4 mM sodium glycodeoxycholate, 26.1 mM bis-Tris buffer, 30 mM NaCl, 109 
pH 6.5) without enzymes at 37 ºC. The solution was stirred every 10 min at 37 ºC 110 
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during 1 h, sonicated for 10 min and stored at 4 ºC until use. Lipids from kiwi seeds 111 
were obtained after 3 times extraction with 10% (wt/vol) acetone of lyophilized kiwi 112 
seeds extract, dissecated and dissolved in cholophorm:methanol 1:2, aliquoted  and 113 
dried under nitrogen stream.   114 
 115 
Simulated gastric and intestinal digestion  116 
For gastric digestions, purified Act d 12 or Act d 13 were dissolved in SGF without 117 
enzyme at 0.2 mg/mL as previously described (8). For some experiments the allergens 118 
were mixed with kiwi lipids, PC or PG vesicles to a final lipid concentration of 6.7 mM. 119 
Porcine pepsin (Sigma, activity: 4720 U/mg) was added at a ratio of enzyme:substrate 120 
1:20 w/w to a final volume of 200 μl of SGF. The digestion was performed at 37 ºC with 121 
moderate shaking. Aliquots of 15 μL were taken at 0, 30 sec, and 1, 5, 10, 20, 30, 60, 122 
120 min and 16 h for SDS-PAGE analysis. The digestion was stopped by increasing 123 
the pH with 5 μL of Na2CO3 0.2 M, adding 10 L of 3x loading buffer and keeping 124 
samples into liquid nitrogen until use. For intestinal digestions, purified allergens with or 125 
without lipids were dissolved in SIF in the presence of 35 μg/mL trypsin and 1.76 126 
μg/mL -chymotrypsin (Worthington Biochemical Co. 200 U/mg and 50 U/mg, 127 
respectively) at a trypsin:chymotrypsin:substrate ratio of 34.5 U:0.44 U:1 mg at final 128 
volume of 200 μL. Digestions were stopped by adding phenylmethylsulfonyl fluoride (2 129 
mM). In all the cases, the aliquots withdrawn at different times were frozen and stored 130 
at -20 ºC until SDS-PAGE and CBS analysis. Control experiments without enzyme or 131 
with BSA instead of allergen were also performed.   132 
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Results 133 
First, proteins contained in lyophilized defatted kiwi seeds extract were separated by 134 
size-exclusion chromatography (Supplementary Fig. 1A). Fractions containing proteins 135 
of around 51 and 12 kDa were pooled in two different batches according to CBS and 136 
IgE-reactivity after SDS-PAGE (Supplementary Fig. 1A, inset). Act d 12 was further 137 
purified to homogeneity from batch 1 by ion-exchange chromatography 138 
(Supplementary Fig. 1B). The purified Act d 12 migrated as a single protein in SDS-139 
PAGE under non-reducing conditions and retained the IgE-binding capacity 140 
(Supplementary Fig. 1B, inset). Act d 13 was purified from batch 2 by RP-HPLC and 141 
also migrated as a single monomer of around 12 kDa under non-reducing conditions 142 
and retained the IgE-binding capacity (Supplementary Fig. 1C, inset).  143 
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Legend to figure 173 
Supplementary Figure 1. (A) Elution profile of kiwi seeds extract after a size-exclusion 174 
chromatography. Two main proteins of around 51 and 12 kDa were separated into 175 
Batch 1 and 2 (shadow in grey). The kiwi seeds extract and the proteins of each batch 176 
were visualized by CBS after SDS-PAGE (inset). (B) Elution profile of Batch 1 after ion-177 
exchange chromatography. Fractions containing the 11S globulin Act d 12 is shadowed 178 
in grey. Purified Act d 12 was visualized by CBS and its IgE-binding capacity was 179 
analyzed with sera from kiwifruit allergic patients (inset). (C) Elution profile of Batch 2 in 180 
RP-HPLC. Fractions containing the 2S albumin Act d 13 is shadowed in grey. Purified 181 
Act d 13 was visualized by CBS and its IgE-binding capacity was analyzed with sera 182 
from kiwifruit allergic patients (inset). 183 
